1,721,180 research outputs found

    Cuschieri, A

    No full text

    Descriptive epidemiology of isolated anal anomalies: a survey of 4.6 million births in Europe.

    No full text
    The prevalence of anal anomalies among 4,618,840 births recorded in 33 EUROCAT registries between 1980 and 1994 was 4.05 per 10,000 births. Of the 1,846 recorded cases, 672 (36.4%) were isolated anal anomalies while 1,174 (63.6%) occurred together with other anomalies. Only isolated anal anomalies were analyzed in this study: 75.5% were atresias, 10.1% of which were above and 89.9% were below the level of the levator ani muscle. Fistula occurred in 53% of supralevator and 37% of infralevator atresia. Other anal anomalies were ectopic anus (3.4%), congenital anal ®stula (14.7%), and persistent cloaca (0.9%). There was a predominance of males in anal atresia without ®stula (male to female (M:F) ratio was 6.7 for supralevator and 2.3 for infralevator atresia), but no signi®cant sex difference in atresias with ®stula. There was a predominance of females in ectopic anus and congenital anal ®stula (M:F0.11 and 0.36 respectively). High frequencies of fetal deaths were recorded in supralevator atresia without ®stula (8.3%) and in persistent cloaca (11.1%). Mean gestational length and mean birth weights were reduced for persistent cloaca but were within normal limits for other isolated anal anomalies. Odds ratios (ORs) for mothers above 35 years were increased for supralevator atresia without ®stula, supralevator atresia with ®stula, and congenital anal ®stula. ORs for mothers below 30 years were slightly increased for supralevator atresia without ®stula and decreased for persistent cloaca. There were marked differences in prevalence and distribution of anal anomalies among the EUROCAT registries. The results indicated that there are epidemiological differences among the various types of anal anomalies which might re ̄ect different embryological origins

    Science, medicine, and the future Capsule endoscopy

    No full text
    Capsule endoscopy was unveiled at Digestive Disease Week 2000 in San Diego, California, USA, by Paul Swain, gastroenterologist at Imperial College St Mary’s Hospital, London, and Given Imaging, a Yoqneam (Israel) company, as the product of collaborative research and development activities between the two groups.1 The past few years have seen advances in this technology, which is now part of established clinical practice in North America, Europe, the Far East, and Australia, particularly for imaging the small bowel. This article describes current clinical applications of capsule endoscopy and looks at future developments

    Anorectal anomalies associated with or as part of other anomalies.

    No full text
    Anorectal anomalies occurring with other anomalies or as part of syndromes were analyzed to determine how their epidemiological characteristics differed from those of isolated anal anomalies. Almost 15% of cases were chromosomal, monogenic or teratogenic syndromes, whereas the rest were of unknown cause including sequences (9.3%), VACTERL associations (15.4%) and multiple congenital anomalies (MCA) (60.2%). Almost half of babies with MCA had one or two VACTERL anomalies with distribution frequencies that did not differ significantly from those in babies with the full VACTERL association. There were considerable differences in the frequency of the VACTERL association among babies with different types of anorectal anomaly. Babies with anal anomalies occurring with sequences, VACTERL or MCA showed the same sex differences as babies with isolated anal anomalies, namely male predominance in anal atresia without fistula or cloaca, no sex difference in anal atresia with fistula, and female predominance in ectopic anus and congenital anal fistula. These anomalies, however, were associated with significantly lower mean gestational lengths and birth weights, and higher frequencies of fetal death and pregnancy termination than babies with isolated anal anomalies. Twins were more frequent in sequences, VACTERL and MCA than in isolated anomalies, monogenic syndromes or chromosome anomalies. Five cases were conjoined twins, representing 15% of all cases of twin pregnancies with an anal anomaly. Indeterminate sex was more frequent in babies with anal atresias without fistula than in those with fistula. Anal anomalies are defects of blastogenesis attributable to disorders in expression of pattern determining genes. The differential sex involvement in different types of anal anomaly may be manifestations of expression of the HY/SRY genes during blastogenesis or of X-linkag

    Synthesis, characterisation and dispersion of zinc oxide nanorods for biomedical applications

    No full text
    Nanoparticles are increasingly being recognised for their potential utility in biomedicine. Here, the authors present a low-temperature, solvo-thermal method to synthesise zinc oxide (ZnO) nanorods using ZnO nanoparticles as precursors, with the addition of low-density polyethylenimine (PEI). This surfactant, which is in regular use in biology, has a double advantage: (i) it catalyses the synthesis owing to the amino groups on its polymeric chain and (ii) it wraps around ZnO nanorods as the crystal grows. The synthesis is followed by scanning electron microscopy, energy-dispersive spectroscopy and spectrophotometric analysis. The length of nanorods was dependent on the reaction time: around 300 nm, 1 mu m and 5 mm, respectively, for 3, 6 and 12 h of reaction time. Toxicology studies showed that cellular response is both dose and size-dependent. Sub-1 mu m ZnO nanorods were found to be internalised by cells and strongly affect cell viability with a process mediated by reactive oxygen species (ROS) production. The internalisation rate of bigger nanostructures is significantly lower, resulting in a moderate cytotoxicity with no detectable ROS production.</p

    Combination of polymer technology and carbon nanotube array for the development of an effective drug delivery system at cellular level

    No full text
    In this article, a carbon nanotube (CNT) array-based system combined with a polymer thin film is proposed as an effective drug release device directly at cellular level. The polymeric film embedded in the CNT array is described and characterized in terms of release kinetics, while in vitro assays on PC12 cell line have been performed in order to assess the efficiency and functionality of the entrapped agent (neural growth factor, NGF). PC12 cell differentiation, following incubation on the CNT array embedding the alginate delivery film, demonstrated the effectiveness of the proposed solution. The achieved results indicate that polymeric technology could be efficiently embedded in CNT array acting as drug delivery system at cellular level. The implication of this study opens several perspectives in particular in the field of neurointerfaces, combining several functions into a single platform
    corecore